Bristol Myers’ Opdivo steps in FDA fast lane for potential first-in-class nod in pre-surgery lung cancernews2022-02-28T14:10:58+00:00February 28th, 2022|Fierce Pharma|
Viatris inks $264M deal to resolve long-running EpiPen pay-for-delay casenews2022-02-28T14:10:29+00:00February 28th, 2022|Fierce Pharma|
After raking in billions with its COVID shot, Moderna faces patent infringement suit related to vaccine delivery technews2022-02-28T14:03:44+00:00February 28th, 2022|Fierce Pharma|
Viatris unloads biosimilar business to partner Biocon for $3.3Bnews2022-02-28T10:19:13+00:00February 28th, 2022|Fierce Pharma|
‘Light up for Rare’ spotlights rare disease to help break the isolation COVID has wroughtnews2022-02-28T09:15:47+00:00February 28th, 2022|Fierce Pharma|
AstraZeneca doubles down on animation—with a ’60s spin this time—in new Breztri ad campaignnews2022-02-26T12:57:23+00:00February 26th, 2022|Fierce Pharma|
Judge backs Johnson & Johnson in bankruptcy ploy for talc litigation, clears way for settlementnews2022-02-25T21:07:14+00:00February 25th, 2022|Fierce Pharma|
EMA expands nods for BMS, Eli Lilly, Novartis drugs and backs Biohaven, VBI, Myovant therapies for first timenews2022-02-25T16:36:49+00:00February 25th, 2022|Fierce Pharma|
Emergent underway with $100M in manufacturing upgrades as it gears up for ‘post-pandemic work’news2022-02-25T15:15:23+00:00February 25th, 2022|Fierce Pharma|
Johnson & Johnson, distributor giants finalize $26B opioid settlement as states pile into landmark dealnews2022-02-25T14:45:47+00:00February 25th, 2022|Fierce Pharma|
